ArticleArchives of virology2025
Construction of a single-cycle replication recombinant infectious laryngotracheitis virus lacking the glycoprotein H gene and evaluation of its role in viral entry and infectivity.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infectious laryngotracheitis virus (ILTV), a significant avian pathogen belonging to the subfamily Alphaherpesvirinae, causes severe respiratory disease, particularly in unvaccinated flocks. In this study, we produced a recombinant ILTV lacking the essential envelope glycoprotein H (gH), a key determinant of viral entry and propagation. To achieve this, we engineered an ILTV mutant with the gH gene replaced by a BleCherry fluorescent reporter cassette. This modification enabled the identification and isolation of recombinant viruses through red fluorescence. To facilitate the replication of this gH-deficient mutant, we generated a stable Vero cell line expressing gH and a green fluorescent protein (GFP) reporter. This engineered cell line proved crucial for generating the recombinant ILTV and allowing controlled single-cycle replication. The recombinant ILTV exhibited enhanced viability across a range of multiplicities of infection (MOIs), although with a significant reduction in overall viral replication. Importantly, the modified virus is unable to replicate in the absence of exogenous gH, minimizing the risks associated with viral spread and unintended infections. This novel single-cycle recombinant ILTV platform holds significant promise for various applications, including safe gene delivery and the development of improved vaccine strategies for enhanced avian health management and disease control.
Indexed as
Identifiers
40299141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.